Clik here to view.
Tekmira reports on protection against deadly Ebola virus
Tekmira Pharmaceuticals (TSX:TKM) has published a series of studies in The Lancet demonstrating the ability of an RNA-interference therapeutic using Tekmira’s SNALP lipid nanoparticle delivery...
View ArticleClik here to view.
Tekmira wins $2.4 million NIH grant
Tekmira Pharmaceuticals (TSX:TKM) and its collaborators at the University of Texas Medical Branch at Galveston, Tex. have received a $2.4 million (U.S.) grant from the U.S. National Institutes of...
View ArticleClik here to view.
Aethlon readies U.S. study of the Hemopurifier
Aethlon Medical (OTCQB:AEMD), sporting FDA approval of an investigational drug exemption (IDE), plans to begin treating patients infected with hepatitis C virus (HCV) early next year in a feasibility...
View ArticleClik here to view.
Clarus starts Tekmira Pharma at buy
Clarus Securities has initiated coverage of Tekmira Pharmaceuticals (NASDAQ:TKMR; TSX:TKM) with a “buy” rating and price target of $22.50, saying the company is delivering multiple paths to value. The...
View ArticleClik here to view.
FDA eases Tekmira’s TKM-Ebola to partial clinical hold
The FDA has verbally confirmed that it has modified a full clinical hold on Tekmira Pharmaceuticals’ (NASDAQ:TKMR; TSX:TKM) TKM-Ebola Investigational New Drug application to a partial clinical hold....
View Article
